Skip to the answer

Topotecan Uses, Dosage, Side Effects and Interactions

Brand name
Hycamtin

Hycamtin was the first topotecan product the FDA approved, in May 1996. A generic is listed for its injections, but not for its capsules.

Topotecan is a chemotherapy medicine (a topoisomerase inhibitor) used to treat small cell lung cancer, metastatic ovarian cancer and cervical cancer, depending on the product.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 19, 2026 Where our facts come from

Quick links

Ask Anything About TopotecanType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Topotecan in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Topotecan (Hycamtin) is a chemotherapy drug for small cell lung cancer and, as an injection, ovarian and cervical cancer, usually a later option after earlier chemotherapy fails; it blocks topoisomerase I, an enzyme cancer cells need to copy DNA, leaving breaks they cannot repair, and it has been around since about 1996, with FDA-approved generics listed. Like most chemotherapy it is hard going, and tiredness, nausea and hair loss are what people notice most. The one thing to watch is its boxed warning for severe myelosuppression (a serious drop in blood counts), so call your care team right away about fever, chills, or unusual bleeding or bruising.

Key Takeaways From the HelloPharmacist Team

  • Expect 21-day cycles, given as a 30-minute IV infusion on the first few days or as capsules once daily for 5 days.
  • Plan on frequent blood tests, because each new cycle starts only once your white cells and platelets have recovered enough.
  • Get help right away for fever with belly pain, or a new cough with trouble breathing, which can signal bowel or lung inflammation.
  • Use effective birth control during treatment and for 6 months after (3 months for men), because topotecan can harm an unborn baby.

How we write and review this content: our editorial policy

FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Topotecan.

Hycamtin can cause severe myelosuppression, meaning a serious drop in your blood cell counts. Your first cycle should only be given if your neutrophil (infection-fighting white cell) and platelet counts are high enough at the start. Your blood counts will be checked regularly. Tell your care team right away about fever, signs of infection, or unusual bleeding or bruising.

Read the full warning on DailyMed →

Topotecan by the Numbers

Strengths
3
across 2 forms
Makers and packagers
6
Earliest FDA record
1996
Rank by Medicaid prescriptions
#1,267 of 1,682 drugs
More prescriptions than 24% of the 1,682 drugs we measure
1,496 prescriptions, Q1–Q4 2025
Other forms and routes

Patient Information Guide for Topotecan

What It’s Used For

Topotecan treats several cancers, depending on the product.

  • Metastatic ovarian cancer after progression on or after earlier chemotherapy (Hycamtin for injection and topotecan hydrochloride for injection, as a single agent).
  • Small cell lung cancer (SCLC) that was platinum-sensitive and progressed at least 60 days after first-line chemotherapy started (topotecan injection products and Hycamtin for injection).
  • Relapsed SCLC in people with a prior complete or partial response who are at least 45 days from the end of first-line chemotherapy (Hycamtin capsules).
  • Stage IV-B, recurrent or persistent cervical cancer not amenable to curative treatment, together with cisplatin (Hycamtin for injection, topotecan hydrochloride for injection and one topotecan injection).

How It Works

Topotecan attaches to topoisomerase I, an enzyme that normally nicks and reseals DNA so it can be copied. By stopping the reseal step, topotecan causes double-strand DNA damage when cells copy their DNA. Cells cannot easily repair this damage, which is thought to be how it kills cancer cells.

Drug Class

Drug Class

  • Topoisomerase Inhibitor
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Topoisomerase Inhibitor

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • Topoisomerase Inhibitors

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Topotecan in the FDA’s index.

From our Patient Information GuideTopotecan attaches to topoisomerase I, an enzyme that normally nicks and reseals DNA so it can be copied. By stopping the reseal step, topotecan causes double-strand DNA damage when cells copy their DNA. Read How Topotecan Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Topotecan in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Topoisomerase 1 (TOP1) inhibitors

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Topotecan is given in repeating 21-day cycles, with dosing based on your body size.

  • Injection: given into a vein over about 30 minutes by a healthcare team, usually for several days at the start of each cycle.
  • Hycamtin capsules: taken by mouth once a day for 5 days, with or without food. Swallow whole.
  • Missed or vomited dose (capsules): do not take an extra dose. Take the next one at the scheduled time.

Doses may be lowered for low blood counts, diarrhea (capsules) or kidney problems. Follow your prescriber and the label.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Topotecan Injection

Ovarian cancer that has spread
For adults
Usual dose 1.5 mg/m2 by IV infusion over 30 minutes daily for 5 days
  • 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity

Limit Do not exceed a single dose of 4 mg intravenously

IV means given into a vein (intravenous).

Small cell lung cancer
For adults
Usual dose 1.5 mg/m2 by IV infusion over 30 minutes daily for 5 days
  • 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle

Limit Do not exceed a single dose of 4 mg intravenously

IV means given into a vein (intravenous).

Cervical cancer
For adults
Usual dose 0.75 mg/m2 by IV infusion over 30 minutes daily on Days 1, 2, and 3
  • 0.75 mg/m2 by intravenous infusion over 30 minutes daily on Days 1, 2, and 3, with cisplatin 50 mg/m2 on Day 1, of a 21-day cycle

Limit Do not exceed a single dose of 4 mg intravenously

IV means given into a vein (intravenous).

Single agent, kidney problems with creatinine clearance 20 to 39 mL/min
For adults
Dose 0.75 mg/m2/day
  • Reduce the dose to 0.75 mg/m2/day

Good to know

Creatinine clearance calculated with Cockcroft-Gault method using ideal body weight

See the Full Dosing Instructions on DailyMed →

Topotecan Taken by Mouth

Small cell lung cancer
Adults Usual dose 2.3 mg/m2 once a day for 5 days

Step by step

  1. 2.3 mg/m2/day orally once daily, with or without food, for 5 consecutive days, starting on Day 1 of a 21-day cycle
  2. Round to the nearest 0.25 mg

Good to know

Swallow capsules whole; same number of capsules each of the 5 days

Capsules, kidney problems with creatinine clearance less than 30 mL/min Usual dose 0.6 mg/m2 once a day

Good to know

Cockcroft-Gault with ideal body weight

Adults with kidney problems (creatinine clearance 30 to 49 mL/min) Usual dose 1.5 mg/m2 once a day

Good to know

Cockcroft-Gault with ideal body weight

See the Full Dosing Instructions on DailyMed →

Side Effects

Many side effects come from effects on the blood and digestive system.

Common side effects

  • Low white blood cell count (neutropenia, leukopenia)
  • Low red blood cell count (anemia)
  • Low platelet count (thrombocytopenia)
  • Nausea and vomiting
  • Diarrhea or constipation
  • Hair loss
  • Tiredness or weakness
  • Fever and pain

When to get medical help

  • Call your care team right away for fever, chills or other signs of infection, since low white blood cells can lead to serious infection or sepsis.
  • Get help for fever with belly pain, which can signal neutropenic colitis (inflamed bowel linked to low white cells). This can be fatal.
  • Report new cough, fever or trouble breathing, which can be signs of interstitial lung disease (lung inflammation).
  • Tell your team about unusual bleeding or bruising, which can come with low platelets.
  • Seek help for signs of a severe allergic reaction, such as swelling or severe itching.
  • Tell the nurse right away about pain, swelling or redness at the IV site, since leakage of the drug outside the vein (extravasation) can occur.
  • For Hycamtin capsules, report severe diarrhea, as treatment may need to be held.

Warnings and Precautions

  • Bone marrow suppression is the biggest risk, with severe drops in white cells, red cells and platelets. Counts are checked often.
  • Neutropenic colitis: low white cells can lead to bowel inflammation, which has been fatal.
  • Interstitial lung disease: reported, some cases fatal. Risk is higher with prior lung disease, lung cancer or chest radiation.
  • Pregnancy: can cause fetal harm.
  • Extravasation: the IV drug leaking outside the vein has been seen, mostly mild but sometimes severe.
  • Diarrhea (capsules): Hycamtin capsules are not given during severe diarrhea.

Interactions

Combining topotecan with other drugs that lower blood counts needs care.

  • Cisplatin and other chemotherapy: more severe bone marrow suppression, so doses may be reduced.
  • Platinum timing: giving a platinum drug on day 1 required lower doses than on day 5.
  • G-CSF: starting it too early can prolong neutropenia, so it is not started until day 6, 24 hours after the last topotecan dose.

Interactions Listed in the FDA-Approved Label

From the Topotecan prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • What happensConcomitant administration of G-CSF can prolong the duration of neutropenia.
    What to doDo not start G-CSF until day 6 of the course, 24 hours after completing topotecan.
  • Platinum agents For example: cisplatin, carboplatin
    What happensMyelosuppression was more severe with cisplatin in Phase 1 trials, and a sequence-dependent interaction was reported; giving the platinum agent on day 1 required lower doses of each agent than giving it on day 5.
    What to doA dose reduction may be necessary.
  • Other cytotoxic agents
    What happensGreater myelosuppression is likely when used in combination with other cytotoxic agents.
    What to doA dose reduction is necessary.
Read the label’s full interactions text

7 DRUG INTERACTIONS G-CSF: Concomitant administration of G-CSF can prolong the duration of neutropenia, so if G-CSF is to be used, do not initiate it until day 6 of the course of therapy, 24 hours after completion of treatment with topotecan hydrochloride for injection. Platinum and Other Cytotoxic Agents: Myelosuppression was more severe when topotecan hydrochloride for injection, at a dose of 1.25 mg/m 2 /day for 5 days, was given in combination with cisplatin at a dose of 50 mg/m 2 in Phase 1 trials. In one trial, 1 of 3 patients had severe neutropenia for 12 days and a second patient died with neutropenic sepsis. Greater myelosuppression is also likely to be seen when topotecan hydrochloride for injection is used in combination with other cytotoxic agents, thereby necessitating a dose reduction. However, when combining topotecan hydrochloride for injection with platinum agents (e.g., cisplatin or carboplatin), a distinct sequence-dependent interaction on myelosuppression has been reported. Coadministration of a platinum agent on day 1 of dosing with topotecan hydrochloride for injection required lower doses of each agent compared to coadministration on day 5 of the dosing schedule for topotecan hydrochloride for injection. For information on the pharmacokinetics, efficacy, safety, and dosing of topotecan hydrochloride for injection at a dose of 0.75 mg/m 2 /day on days 1, 2, and 3 in combination with cisplatin 50 mg/m 2 on day 1 for cervical cancer, see Dosage and Administration, Adverse Reactions, Clinical Pharmacology, and Clinical Studies. Do not initiate G-CSF until 24 hours after completion of treatment with topotecan hydrochloride for injection. Concomitant administration can prolong duration of neutropenia. Greater myelosuppression is likely to be seen when used in combination with other cytotoxic agents.

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Do not use with a history of severe allergic reaction to topotecan or its ingredients.
  • Topotecan injection should not be used with severe bone marrow depression.
  • Blood counts must be high enough before the first cycle.
  • Pregnancy should be ruled out before starting. Use effective contraception during treatment (6 months after for women, 3 months after for men).
  • Do not breastfeed during treatment and for 1 week after the last dose.
  • Kidney function matters, as doses are lowered for reduced kidney function.
  • Not established for children. Older adults had no overall differences in safety or effectiveness.
  • Tell your doctor about lung disease or prior chest radiation.

Overdose

The main problem with too much topotecan is bone marrow suppression. Mouth sores, higher liver enzymes, and severe infection have also been reported. There is no known antidote. Treatment is monitoring blood counts and supportive care, such as G-CSF and antibiotics as appropriate.

Half-Life and How Your Body Processes It

After an IV infusion, topotecan is cleared fairly quickly, with a terminal half-life of about 2 to 3 hours. About 35% is bound to plasma proteins. It is changed in the body in a pH-dependent way and into a minor metabolite. The kidneys are an important route of elimination, and most of the drug is cleared in urine and feces. Reduced kidney function slows clearance, which is why doses are adjusted.

Storage

Store at 20° to 25°C (68° to 77°F) . Protect from light; product is light-sensitive.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Supplements and Herbs That Interact With Topotecan

From the licensed clinical database we use, rolled up per supplement, most serious first.

19 supplements and herbal products have documented interactions with Topotecan in the licensed clinical database we use.

Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.

  • 1Major
  • 9Moderate
  • 9Minor

See the other 11

Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Topotecan: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Topotecan — the kind of thing our pharmacy team would talk through with you at the counter.

What is topotecan used for?

It is a chemotherapy medicine. Depending on the product, it treats small cell lung cancer, metastatic ovarian cancer, and, with cisplatin, advanced or recurrent cervical cancer. Your oncology team picks the form that fits your situation.

How is topotecan given?

The injection goes into a vein over about 30 minutes, and Hycamtin capsules are swallowed whole once a day for 5 days, with or without food. Both follow a 21-day cycle. Do not chew or crush the capsules.

What happens if I miss a dose or throw up after taking Hycamtin capsules?

Do not take an extra dose. Just take your next dose at the usual scheduled time, and let your care team know what happened.

What side effects should I expect, and which ones should I call about?

Low blood counts, nausea, vomiting, diarrhea or constipation, hair loss and tiredness are common. Call right away for fever, signs of infection, belly pain with fever, unusual bleeding, new cough or trouble breathing, or severe diarrhea.

Why do I need so many blood tests?

Topotecan can seriously lower your white cells, red cells and platelets. Your counts must be high enough before you start and recover before each new cycle. Regular tests help your team adjust your treatment safely.

Is it safe during pregnancy or breastfeeding?

No. Topotecan can harm an unborn baby, so pregnancy should be ruled out before starting and you should use effective contraception. Do not breastfeed during treatment and for 1 week after the last dose.

Is topotecan available over the counter?

No. Topotecan is a prescription medicine: every topotecan product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was topotecan first available?

The earliest FDA record we hold for topotecan is from 1996: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when topotecan was first used.

Who makes topotecan?

6 companies currently list topotecan products in the FDA's NDC Directory, including Accord Healthcare Inc., Sandoz Inc, Actavis Pharma, Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of topotecan?

Topotecan is the generic name. Its brand name is Hycamtin. Generic versions are listed under the name topotecan.

What is the generic name of Hycamtin?

The generic name of Hycamtin is topotecan. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is topotecan?

Topotecan belongs to the drug class Topoisomerase Inhibitor, its established pharmacologic class on the FDA label.

Is there a generic version of topotecan?

Yes. FDA-approved generic versions of topotecan are listed in the FDA's National Drug Code Directory. A listing does not prove that every pharmacy stocks one, so your pharmacy can tell you which version it carries.

What strengths does topotecan come in?

Topotecan is listed in the FDA's National Drug Code Directory in these forms and strengths. Injection (into a vein): 4 mg/4 mL. Capsule (by mouth): 0.25 mg and 1 mg. A listing does not mean every pharmacy stocks every strength.

Is there a topotecan shortage?

No. Topotecan is not on the FDA's drug shortage list as of Nov 20, 2026. A single pharmacy can still run short for a while without a national shortage, and your pharmacist can tell you what they are seeing.

Where can I read the topotecan prescribing information (package insert)?

The full FDA-approved prescribing information for topotecan, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Hospira, Inc.'s, revised Feb 1, 2021, and links to it on DailyMed.

Can you crush topotecan?

Some forms of topotecan are on our Do Not Crush list of tablets and capsules that should not be crushed or chewed: Hycamtin (capsule); topotecan hydrochloride (capsule). Crushing or splitting a hazardous drug can expose whoever handles it. A form that is not on the list may still come with its own instructions, so check the label and ask your pharmacist before you crush, split or open any medicine. Each listed form’s reason and instructions are on our Do Not Crush list.

Is topotecan gluten free?

No topotecan label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten, and none names a starch, dextrin or maltodextrin without saying where it comes from. We read the FDA labels of 8 topotecan products from 6 companies. A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's topotecan by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See topotecan inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Topotecan

Skip the scrolling. Ask in your own words and get an answer from Topotecan’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Topotecan’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Topotecan on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, usually within a day.
Detailed Data & References for Topotecan Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Topotecan Forms and Strengths (How It Comes)

Topotecan comes in 2 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Topotecan inactive ingredients by manufacturer.

Injection

Into a vein
Brands Hycamtin (the first brand, 1996)
How this form is used
What it may be used for
  • Hycamtin for injection and topotecan hydrochloride for injection are used for metastatic ovarian cancer, platinum-sensitive small cell lung cancer, and (with cisplatin) Stage IV-B, recurrent or persistent cervical cancer.
  • Topotecan injection products are used for platinum-sensitive small cell lung cancer after first-line chemotherapy.
Important instructions
  • Hycamtin for injection is given as an IV infusion over about 30 minutes on a 21-day cycle.
  • Topotecan injection concentrate is diluted before being infused over 30 minutes and is handled as a cytotoxic drug.
  • Topotecan injection doses are lowered for certain kidney function levels and for severe drops in blood counts.
Available strengths 2 strengths
6 FDA-listed product records ⓘ

Capsule

By mouth
Brands Hycamtin (the first brand, 1996)
How this form is used
What it may be used for
  • Hycamtin capsules are used for relapsed small cell lung cancer in people with a prior complete or partial response who are at least 45 days from the end of first-line chemotherapy.
Important instructions
  • Hycamtin capsules are taken by mouth once daily for 5 days in a row, starting each 21-day cycle, with or without food.
  • Swallow Hycamtin capsules whole. Do not chew, crush or divide them.
  • If you miss a Hycamtin dose or vomit after a dose, do not take an extra dose. Take the next dose at the scheduled time.
  • Hycamtin capsules should not be given during Grade 3 or 4 diarrhea.
Available strengths 2 strengths
2 FDA-listed product records ⓘ

Topotecan on the U.S. Market: Products, Makers and Brands

How Topotecan appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

6 companies list 8 Topotecan product records with the FDA, mostly as injection, capsule; the earliest marketing or approval year on record is 1996. The one brand name in the directory today is Hycamtin; the rest are generics.

2
Dose forms ⓘ
6
Labelers (makers, repackagers, distributors)
1
Brand names ⓘ
8
FDA-listed product records ⓘ
1996
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (2) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

Accord Healthcare Inc.25%
Sandoz Inc25%
Actavis Pharma, Inc.13%
Fresenius Kabi USA, LLC13%
Hospira, Inc.13%
Novartis Pharmaceuticals Corporation13%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely Topotecan Is Used (Medicaid Data)

How many Topotecan prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

1,496
Medicaid prescriptions filled (Q1–Q4 2025)
$154,127 paid by Medicaid, before rebates

How commonly is Topotecan prescribed? Of the 1,682 medications we measure, Topotecan ranks #1,267 by Medicaid prescriptions — more than 25% of them.

Where Topotecan ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Topotecan product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 4 mL / 1 mg/mL injection is the most-dispensed Topotecan product — about 70% of these Medicaid prescriptions.

4 ML topotecan 1 MG/ML Injection Most dispensed

1,048 Medicaid prescriptions (Q1–Q4 2025) 70% of Topotecan prescriptions shown $52,802 paid by Medicaid, before rebates ≈ $50 per prescription, before rebates

1 of 5 listed NDCs had Medicaid claims. RxNorm 1799424

topotecan 4 MG Injection

436 Medicaid prescriptions (Q1–Q4 2025) 29% of Topotecan prescriptions shown $40,159 paid by Medicaid, before rebates ≈ $92 per prescription, before rebates

3 of 8 listed NDCs had Medicaid claims. RxNorm 1799416

topotecan 1 MG Oral Capsule

12 Medicaid prescriptions (Q1–Q4 2025) <1% of Topotecan prescriptions shown $61,165 paid by Medicaid, before rebates ≈ $5,097 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 747193

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 5 of the 15 listed Topotecan NDCs had Medicaid claims.

Compare Topotecan Products

A representative set of FDA-listed product records for Topotecan — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Capsule
0.25 mg Oral Sandoz Inc NDA View NDC →
1 mg Oral Sandoz Inc NDA View NDC →
💊Injection
4 mg/4 mL Intravenous Accord Healthcare, Inc. ANDA View NDC →
1 mg/mL Intravenous Accord Healthcare Inc. ANDA View NDC →
4 mg/4 mL Intravenous Actavis Pharma, Inc. ANDA View NDC →
4 mg/4 mL Intravenous Fresenius Kabi USA, LLC ANDA View NDC →
1 mg/mL Intravenous Hospira, Inc. NDA View NDC →
4 mg/4 mL Intravenous Novartis Pharmaceuticals Corporation NDA View NDC →

Showing 8 of 8 products — FDA National Drug Code Directory. See every product, package size and price: browse all 8 Topotecan NDCs →

Topotecan Side Effects Reported to the FDA (FAERS)

After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Topotecan — a signal of what to watch for, not proof the drug caused it.

The effects most often named in FDA reports that mention Topotecan are febrile neutropenia, anaemia, death; about 92% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.

6,942
Reports mentioning it
92%
Reported as serious
12
Distinct effects shown
Most reported effects
Febrile Neutropenia
603
Anaemia
580
Death
573
Neutropenia
559
Nausea
477
Disease Progression
457
Thrombocytopenia
453
Pyrexia
449
Vomiting
437
Fatigue
337
Age groups
Child · 317Adult · 249Infant · 106Elderly · 87Adolescent · 39Neonate · 12

Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Topotecan in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.

Topotecan FDA Approval History

How Topotecan went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.

Topotecan was first approved by the FDA in 1996 (Brand: HYCAMTIN · Sandoz); the first generic version was approved in 2010. It remains available in U.S. pharmacies today.

1996
Brand approved
Brand: HYCAMTIN · Sandoz
2010
First generic approved
Lower-cost ANDA competition begins
2026
Available today
Active in U.S. pharmacies

Source: Drugs@FDA.

Topotecan Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Topotecan recalls since July 2021.

✅No Topotecan recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Topotecan in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
3
Strengths
5
Forms in current FDA listings
3 of 3
In current FDA listings No current FDA listing
Ingredient (IN) Topotecan RxCUI 57308
  1. Dose form (SCDF) Injectable Solution RxCUI 376889
    In current FDA listings
    Its strength (SCD)
  2. Dose form (SCDF) Injection RxCUI 1799415
    In current FDA listings
    Its 2 strengths (SCD)
  3. Dose form (SCDF) Oral Capsule RxCUI 747192
    In current FDA listings
    Its 2 strengths (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Topotecan Brand Names

Topotecan has one brand name on record: Hycamtin. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Hycamtin the first brand, 1996

Who Makes Topotecan: Manufacturers and Labelers

6 companies list Topotecan products with the FDA. By number of product records, the largest are Accord Healthcare Inc., Sandoz Inc, Actavis Pharma, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Accord Healthcare Inc. 2 Sandoz Inc 2 Actavis Pharma, Inc. 1 Fresenius Kabi USA, LLC 1 Hospira, Inc. 1 Novartis Pharmaceuticals Corporation 1

Sources for This Topotecan Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Feb 1, 2021, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Topotecan.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 7 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
7
Finished products in the current FDA directory
8
Companies listing them (makers, repackagers, distributors)
6
FDA labeler codes behind them ⓘ
6
Linked representative label ⓘ
Hospira, Inc.
Linked label effective
Feb 1, 2021
Composite sections available
25
Linked SPL Set ID
1d4e1cce-c57e-4a8b-be96-f95a2778e221
Linked SPL Document ID
293334d4-88f2-4ec2-9eed-20975ff65c0a
Open the linked representative label on DailyMed ↗
NDC package records associated with this linked SPL 1

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Hospira, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →